Drug Trial Radar · NCT02101268
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Last checked: Nov 20, 2026Latest source record: May 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Jun 19, 2014
Primary completion
Jul 28, 2016
Study completion Apr 25, 2019
Sponsor
- Lead sponsor
- Sierra Oncology LLC - a GSK companyIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) who were treated with ruxolitinib as measured by splenic response rate at Week 24 (SRR24). Participants will be randomized to receive either MMB or BAT for 24 weeks during the randomized treatment phase, after which they will be eligible to receive MMB in an extended treatment phase for up to an additional 204 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those subjects planning to continue treatment with MMB following the end of the study, the End of Treatment, 30-day, 12-Week, and survival follow-up visits are not required.
Conditions
- Primary Myelofibrosis (PMF)
- Post-polycythemia Vera (Post-PV)
- Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
MomelotinibDrug
Momelotinib tablet administered orally once daily
Best Available Therapy (BAT)Drug
Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Splenic Response Rate at Week 24Time frame: Week 24
Locations
48 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Gainesville, Florida
Site not named
Atlanta, Georgia
Site not named
Kansas City, Kansas
Site not named
Baltimore, Maryland
Site not named
St Louis, Missouri
Site not named
Albuquerque, New Mexico
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cleveland, Ohio
Site not named
Pittsburgh, Pennsylvania
Site not named
Houston, Texas
Site not named
Montreal, Canada
Site not named
Toronto, Canada
Site not named
Edmonton, Alberta, Canada
Site not named
Lille, France
Site not named
Marseille, France
Site not named
Nantes, France
Site not named
Paris, France
Site not named
Pierre-Bénite, France
Site not named
Toulouse, France
Site not named
Villejuif, France
Site not named
Cologne, Germany
Site not named
Dresden, Germany
Site not named
Hamburg, Germany
Site not named
Mannheim, Germany
Site not named
Ashkelon, Israel
Site not named
Haifa, Israel
Site not named
Jerusalem, Israel
Site not named
Tel Aviv, Israel
Site not named
Bologna, Italy
Site not named
Florence, Italy
Site not named
Genova, Italy
Site not named
Milan, Italy
Site not named
Novara, Italy
Site not named
Roma, Italy
Site not named
Varese, Italy
Site not named
Badalona, Spain
Site not named
Barcelona, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.